瓣中瓣经导管主动脉瓣置换术与孤立性再次外科主动脉瓣置换术的比较
本研究为回顾性研究,比较198例瓣中瓣经导管主动脉瓣置换术(ViV TAVR)与147例再次孤立性外科主动脉瓣置换术(redo SAVR)患者。两组手术死亡率均为2%,但redo SAVR组观察与预期手术死亡率比值更高(1.2 vs 0.32)。redo SAVR组术后30天和1年平均跨瓣压差更低、心力衰竭再入院累积发生率更低,但输血、因出血再手术、新发肾衰竭需透析及术后需永久起搏器的比例更高。多因素Cox回归显示ViV TAVR与redo SAVR相比死亡风险无显著增加(HR 1.39;95%CI 0.65-2.99;P=0.40)。
要点
- ViV TAVR与redo SAVR手术死亡率均为2%,但redo SAVR组观察与预期死亡率比值更高(1.2 vs 0.32)。
- redo SAVR组术后30天和1年平均跨瓣压差显著低于ViV组。
- redo SAVR组心力衰竭再入院累积发生率低于ViV组,但术后并发症更多。
核心结论
- ViV TAVR与redo SAVR的死亡率相当。
- redo SAVR组术后平均跨瓣压差更低、心力衰竭再入院更少,但术后并发症更多,尽管其基线风险更低。
研究设计与样本
- 回顾性研究,使用本机构经导管主动脉瓣置换术(2013-2022年)和外科主动脉瓣置换术(2011-2022年)数据库。
- 比较ViV TAVR患者(198例)与再次孤立性SAVR患者(147例),分析临床和超声心动图结局,采用Kaplan-Meier生存估计和Cox回归,并生成心力衰竭再入院的累积发生率函数。
主要发现
- 共实施4200例TAVR和2306例孤立性SAVR,其中ViV TAVR 198例,redo SAVR 147例。
- 两组手术死亡率均为2%,但redo SAVR组观察与预期手术死亡率比值高于ViV组(1.2 vs 0.32)。
- redo SAVR组较ViV组更可能需要输血、因出血再手术、新发肾衰竭需透析及术后需永久起搏器。
- redo SAVR组术后30天和1年平均跨瓣压差显著低于ViV组。
- 1年Kaplan-Meier生存估计相当,多因素Cox回归显示ViV TAVR与redo SAVR相比死亡风险无显著增加(HR 1.39;95%CI 0.65-2.99;P=0.40)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes of patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) versus redo surgical aortic valve replacement (SAVR). METHODS: This was a retrospective study using institutional databases of transcatheter (2013-2022) and surgical (2011-2022) aortic valve replacements. Patients who underwent ViV TAVR were compared with patients who underwent redo isolated SAVR. Clinical and echocardiographic outcomes were analyzed. Kaplan-Meier survival estimation and Cox regression were performed. Cumulative incidence functions were generated for heart failure readmissions. RESULTS: A total of 4200 TAVRs and 2306 isolated SAVRs were performed. Of these, there were 198 patients who underwent ViV TAVR and 147 patients who underwent redo SAVR. Operative mortality was 2% in each group, but observed to expected operative mortality in the redo SAVR group was higher than in the ViV TAVR group (1.2 vs 0.32). Those who underwent redo SAVR were more likely to require transfusions and reoperation for bleeding, to have new-onset renal failure requiring dialysis, and to require a permanent pacemaker postoperatively than those in the ViV group. Mean gradient was significantly lower in the redo SAVR group than in the ViV group at 30 days and 1 year. Kaplan-Meier survival estimates at 1 year were comparable, and on multivariable Cox regression, ViV TAVR was not significantly associated with an increased hazard of death compared with redo SAVR (hazard ratio, 1.39; 95% CI, 0.65-2.99; P = .40). Competing-risk cumulative incidence estimates for heart-failure readmissions were higher in the ViV cohort. CONCLUSIONS: ViV TAVR and redo SAVR were associated with comparable mortality. Patients who underwent redo SAVR had lower postoperative mean gradients and greater freedom from heart failure readmissions, but they also had more postoperative complications than the VIV group, despite their lower baseline risk profiles.
引用
- Yousef S, Serna-Gallegos D, Iyanna N, et al. Valve-in-valve transcatheter aortic valve replacement versus isolated redo surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2023. PMID: 37399942. doi:10.1016/j.jtcvs.2023.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。